| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) M Petri, IN Bruce, T Dörner, Y Tanaka, EF Morand, KC Kalunian, ... The Lancet 401 (10381), 1011-1019, 2023 | 63 | 2023 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) EF Morand, EM Vital, M Petri, R van Vollenhoven, DJ Wallace, M Mosca, ... The Lancet 401 (10381), 1001-1010, 2023 | 55 | 2023 |
| Learning gene regulatory networks from next generation sequencing data B Jia, S Xu, G Xiao, V Lamba, F Liang Biometrics 73 (4), 1221-1230, 2017 | 35 | 2017 |
| An imputation–regularized optimization algorithm for high dimensional missing data problems and beyond F Liang, B Jia, J Xue, Q Li, Y Luo Journal of the Royal Statistical Society Series B: Statistical Methodology …, 2018 | 31 | 2018 |
| Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study JS Smolen, L Xie, B Jia, PC Taylor, G Burmester, Y Tanaka, A Elias, ... Rheumatology 60 (5), 2256-2266, 2021 | 25 | 2021 |
| Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial T Dörner, RF van Vollenhoven, A Doria, B Jia, JA Ross Terres, ME Silk, ... Arthritis research & therapy 24 (1), 112, 2022 | 24 | 2022 |
| Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy PC Taylor, R Alten, JMÁ Gracia, Y Kaneko, C Walls, A Quebe, B Jia, ... RMD open 8 (1), e001994, 2022 | 19 | 2022 |
| Joint bayesian-incorporating estimation of multiple gaussian graphical models to study brain connectivity development in adolescence A Zhang, B Cai, W Hu, B Jia, F Liang, TW Wilson, JM Stephen, ... IEEE transactions on medical imaging 39 (2), 357-365, 2019 | 12 | 2019 |
| STAT5A and STAT5B have opposite correlations with drug response gene expression V Lamba, B Jia, F Liang Biochemical and biophysical research communications 479 (2), 117-124, 2016 | 11 | 2016 |
| Learning moral graphs in construction of high-dimensional Bayesian networks for mixed data S Xu, B Jia, F Liang Neural computation 31 (6), 1183-1214, 2019 | 10 | 2019 |
| POS0190 efficacy and safety of baricitinib in patients with systemic lupus erythematosus: results from two randomised, double-blind, placebo-controlled, parallel-group, phase 3 … EF Morand, Y Tanaka, R Furie, E Vital, R van Vollenhoven, K Kalunian, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 327-328, 2022 | 9 | 2022 |
| Joint estimation of multiple mixed graphical models for pan‐cancer network analysis B Jia, F Liang Stat 9 (1), e271, 2020 | 6 | 2020 |
| Markov neighborhood regression for high-dimensional inference F Liang, J Xue, B Jia Journal of the American Statistical Association 117 (539), 1200-1214, 2022 | 5 | 2022 |
| Fast hybrid Bayesian integrative learning of multiple gene regulatory networks for type 1 diabetes B Jia, F Liang Biostatistics, 2019 | 5 | 2019 |
| Maintenance of patient-reported outcomes in baricitinib-treated patients with moderate-to-severe active rheumatoid arthritis: post hoc analyses from two phase 3 trials D Sholter, J Wu, B Jia, H Zhang, K Griffing, J Birt, PJS Reis, H Liu, ... Rheumatology and Therapy 9 (2), 541-553, 2022 | 4 | 2022 |
| Efficacy of long-term treatment with once-daily baricitinib 2 mg in patients with active rheumatoid arthritis: post hoc analysis of two 24-week, phase III, randomized … AF Wells, B Jia, L Xie, GJ Valenzuela, EC Keystone, Z Li, AK Quebe, ... Rheumatology and Therapy 8 (2), 987-1001, 2021 | 4 | 2021 |
| Learning Gene Regulatory Networks with High-Dimensional Heterogeneous Data B Jia, F Liang New Frontiers of Biostatistics and Bioinformatics, 305-327, 2018 | 4 | 2018 |
| Patient disease trajectories in baricitinib-2 mg-treated patients with rheumatoid arthritis and inadequate response to biologic DMARDs M Genovese, M Weinblatt, J Wu, B Jia, A Quebe, L Sun, YF Chen, C Helt, ... ARTHRITIS & RHEUMATOLOGY 71, 2019 | 3 | 2019 |
| Efficacy of Long-term Treatment With Baricitinib 2 mg in Patients With Active Rheumatoid Arthritis A Wells, B Jia, L Xie, G Valenzuela, E Keystone, Z Li, A Quebe, K Griffing, ... JOURNAL OF RHEUMATOLOGY 48 (7), 1175-1175, 2021 | 2 | 2021 |
| Baricitinib provides better pain relief across all disease activity levels compared with placebo and adalimumab in rheumatoid arthritis P Taylor, J Pope, K Ikeda, X Zhang, B Jia, H Zhang, A Quebe, YF Chen, ... ARTHRITIS & RHEUMATOLOGY 71, 2019 | 2 | 2019 |
